[Application of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia--Review].

The development of medical technology and the extension of lifespan have promoted population aging, and malignant blood diseases are gradually becoming common in the elderly. Among them, the most common is acute myeloid leukemia (AML), with a median age at diagnosis of 68 years old. Due to poor clinical conditions, severe comorbidities, poor tolerance to intensive therapy, as well as unfavorable or complex cytogenetics and multidrug resistance, elderly AML patients have a poorer prognosis and increased risks of treatment-related toxicity and mortality. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the optimal treatment strategies for elderly AML patients. With improvements in reduced-intensity conditioning (RIC), the expansion of donor selection, the optimization of graft-versus-host disease (GVHD) prevention regimen, and the progress of supportive care, more elderly AML patients have been choosing allo-HSCT. This article reviews the recent applications of allo-HSCT in elderly AML patients.